Summit Therapeutics Inc
SMMT
Company Profile
Business description
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Contact
601 Brickell Key Drive
Suite 1000
MiamiFL33131
USAT: +1 305 203-2034
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
265
Stocks News & Analysis
stocks
ASX miner weathers the storm with strong commodity prices
Lower volumes due cyclone activity but revenues hold steady.
stocks
Eli Lilly earnings: Mounjaro/Zepbound’s massive volume growth more than counters price pressure
We’ve raised our fair value estimate of Lilly stock.
stocks
OpenAI missed multiple revenue targets - here’s why it likely won’t IPO this year
Plus, whichever AI company IPOs first defines what “good” looks like.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,954.70 | 21.20 | -0.24% |
| CAC 40 | 8,114.84 | 0.00 | 0.00% |
| DAX 40 | 24,292.38 | 337.82 | 1.41% |
| Dow JONES (US) | 49,652.14 | 790.33 | 1.62% |
| FTSE 100 | 10,298.73 | 80.09 | -0.77% |
| HKSE | 25,776.53 | 335.31 | -1.28% |
| NASDAQ | 24,892.31 | 219.07 | 0.89% |
| Nikkei 225 | 59,513.12 | 228.20 | 0.38% |
| NZX 50 Index | 13,039.20 | 135.89 | 1.05% |
| S&P 500 | 7,209.01 | 73.06 | 1.02% |
| S&P/ASX 200 | 8,729.80 | 21.20 | -0.24% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |